Navigation Links
VIVUS to Present at Three Upcoming Investor Conferences in March
Date:2/25/2011

MOUNTAIN VIEW, Calif., Feb. 25, 2011 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at three investment conferences during the month of March.  The conference presentation schedule is as follows:Citi's 2011 Global Health Care ConferenceMarch 1, 2011 at 4:00 p.m. ETHilton New York Hotel, New York, NYCowen and Company 31st Annual Health Care ConferenceMarch 8, 2011 at 8:45 a.m. ETThe Boston Marriott Copley Place, Boston, MAROTH Capital Partners 23rd Annual OC Growth Stock ConferenceMarch 15, 2011 at 11:30 a.m. PTRitz-Carlton, Laguna Niguel, CAA live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA® is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

CONTACT:VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officerbkorb@troutgroup.com650-934-5200646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. VIVUS Provides Regulatory Update on QNEXA NDA
2. VIVUS to Present at the 2011 JP Morgan Healthcare Conference
3. VIVUS Submits Briefing Document to FDA, Announces Follow-up Meeting to Discuss QNEXA®
4. VIVUS to Present at Two Upcoming Investor Conferences
5. VIVUS Reports Third Quarter and First Nine Months 2010 Financial Results
6. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA®
7. VIVUS Announces Sale of MUSE Assets to Meda
8. VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
9. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
10. VIVUS to Present at Lazard Capital Markets Healthcare Conference
11. VIVUS Announces Promotion of Peter Tam to President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... , June 24, 2016  Collagen Matrix, ... design, development and manufacturing of collagen and mineral ... announced today that Bill Messer has ... Marketing to further leverage the growing portfolio of ... devices. Bill joins the Collagen Matrix ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
Breaking Medicine Technology:
(Date:6/26/2016)... Aliso Viejo, California (PRWEB) , ... June 26, 2016 , ... ... for Final Cut Pro X. , "Film editors can give their videos a whole ... artistically," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from PsychTests.com reveals that behind the tendency to set low expectations ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):